^
Association details:
| Biomarker: | CD8 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | tifcemalimab (TAB004) (BTLA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.
Published date:
05/26/2022
Excerpt:
A total of 25 patients with solid tumor were enrolled in the Part A of this phase I study (NCT04137900). The median age was 62 (range 32-85) years with 16 (64%) male patients. Patients were heavily pretreated with a median of 4 prior lines of therapy. Fifteen (60%) patients received and progressed upon prior anti-PD-1/L1 therapy.Icatolimab monotherapy were well tolerated in all doses evaluated and showed preliminary clinical efficacy as a monotherapy. Icatolimab in combination with toripalimab (anti-PD-1) for the treatment of patients with advanced solid tumors is currently ongoing.
DOI:
10.1200/JCO.2022.40.16_suppl.2643
Trial ID:
